Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85014 | 0.84 | TSHR (0.42) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| Ethylene SCHEMBL28118800 | 0.79 | TSHR (0.38) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL16675245 | 0.78 | TSHR (0.33) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL16675268 | 0.78 | ACLY (0.38) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL20635493 | 0.75 | TSHR (0.35) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL16675253 | 0.75 | ACLY (0.35) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL16305062 | 0.73 | ACLY (0.57) | TSHRACLYACACBACACA | |
| SCHEMBL16305064 | 0.73 | ACLY (0.57) | TSHRACLYACACBACACA | |
| SCHEMBL8359184 | 0.72 | TSHR (0.36) | TSHRALDH1A1ACLYCYP2D6CYP2C19 | |
| SCHEMBL797973 | 0.72 | TSHR (0.47) | TSHRALDH1A1ACLYCYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | TSHR 4804/4885ALDH1A1 4432/4885ACLY 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.